Join to View Full Profile
55 Fruit St# STREET1Boston, MA 02114
Phone+1 617-724-1124
Dr. Hobbs is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- I am a board certified hematologist and oncologist. I am the clinical director of the adult leukemia service at MGH. My clinical and research focus is the treatment of patients with leukemia, specifically patients with myeloproliferative neoplasms.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2011 - 2014
Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 2008 - 2011
Icahn School of Medicine at Mount SinaiClass of 2008
Certifications & Licensure
MA State Medical License 2010 - 2027
NH State Medical License 2021 - 2027
ME State Medical License 2020 - 2026
RI State Medical License 2020 - 2026
FL State Medical License 2021 - 2023
NY State Medical License 2011 - 2015
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study of Regorafenib in Patients With Advanced Myeloid Malignancies Start of enrollment: 2017 Apr 17
- PD-1 Inhibition in Advanced Myeloproliferative Neoplasms Start of enrollment: 2017 Jun 14
- Ruxolitinib Pre-, During- and Post-HSCT for Patients with Primary or Secondary Myelofibrosis. Start of enrollment: 2018 Aug 28
- Join now to see all
Publications & Presentations
PubMed
- Highlights from MPN Asia 2025: Advances in Molecular Pathogenesis and Therapeutic Strategies in Myeloproliferative Neoplasms.Prithviraj Bose, Zhijian Xiao, Hans C Hasselbalch, Josef T Prchal, Minghui Duan
Current Hematologic Malignancy Reports. 2025-07-12 - Beyond Thrombosis: Pulmonary Hypertension and Heart Failure in Patients With Myeloproliferative Neoplasms: JACC: CardioOncology State-of-the-Art Review.Orly Leiva, Olivia Liu, Anthony Kanelidis, Stanley Swat, Leo Gozdecki
JACC. Cardiooncology. 2025-07-03 - Ixazomib in addition to chemotherapy for the treatment of acute myeloid leukemia in older adults.Philip C Amrein, Frederic I Preffer, Geoffrey Fell, Eyal C Attar, Rupa Narayan
Leukemia & Lymphoma. 2025-07-01
Journal Articles
- Effectiveness of Integrated Palliative and Oncology Care for Patients with Acute Myeloid LeukemiaAreej El-Jawahri, Thomas W Leblanc, Selina M Luger, Bhavana Bhatnagar, Alison R Walker, Amir T Fathi, Andrew M Brunner, Gabriela S Hobbs, Jennifer S Temel, JAMA Oncology
Abstracts/Posters
- Pregnancy Outcomes, Risk Factors, and Gestational Cell Count Trends in Pregnant Women with Essential Thrombocythemia and Polycythemia VeraGabriela S. Hobbs, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Quality of Life and Psychological Distress in Patients with Acute Myeloid Leukemia (AML)2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Phase I Study of the Antibody-Drug Conjugate Brentuximab Vedotin Combined with Re-Induction Chemotherapy in Patients with CD30-Expressing Relapsed/Refractory Acute Mye...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
“Remarkable” Survival Data for ADC Regimen in Relapsed/Refractory Diffuse Large B-Cell LymphomaJune 17th, 2025- New Phase 3 Data Back Regimen as “The Major GVHD Prophylaxis,” Expert SaysJune 17th, 2025
- Phase 3 Data From EHA 2025 Support New Option for High-Risk Blood CancerJune 16th, 2025
- Join now to see all
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
